Share_老虎社区_美港股上老虎

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":803555528,"tweetId":"803555528","gmtCreate":1627451105564,"gmtModify":1633764854719,"author":{"id":3582085254286979,"idStr":"3582085254286979","authorId":3582085254286979,"authorIdStr":"3582085254286979","name":"Celia24","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":11,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Share&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Share&nbsp;</p></body></html>","text":"Share","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/803555528","repostId":1107532514,"repostType":4,"repost":{"id":"1107532514","kind":"news","pubTimestamp":1627449908,"share":"https://ttm.financial/m/news/1107532514?lang=&edition=full","pubTime":"2021-07-28 13:25","market":"us","language":"en","title":"Chinese Drug Developer I-Mab Proceeds With Shanghai Dual Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=1107532514","media":"Bloomberg","summary":"I-Mab is progressing with its dual listing plans on Shanghai’s Nasdaq-style exchange as the drug dev","content":"<p>I-Mab&nbsp;is progressing with its dual listing plans on Shanghai’s Nasdaq-style exchange as the drug developer seeks to expand its investor base.</p>\n<p>The Chinese company’s board approved the proposed STAR board listing and has hiredChina International Capital Corp.to work on its initial public offering tutorial, according to astatementTuesday. The company, which is traded in New York, aims to complete the Shanghai offering next year. It didn’t specify a fundraising target.</p>\n<p>”We are making concrete progress in our plan to pursue further equity listings on Greater China stock exchanges, including Shanghai Stock Exchange and Hong Kong Stock Exchange,” Jielun Zhu, chief financial officer of I-Mab, said in the statement. “The potential dual listing on the STAR board in China will enable us to tap into a complementary shareholder base in the onshore market.”</p>\n<p>Based in Shanghai, I-Mab focuses on treatments in the therapeutic areas of immuno-oncology and autoimmune diseases. It has a pipeline of more than 10 clinical and pre-clinical stage drug candidates, with offices in Beijing, Shanghai, Hangzhou, Hong Kong and the U.S.</p>\n<p>I-Mab raised about $114 million in a U.S. IPO in January 2020, followed by an additional share sale of $204 million earlier this year. The company is seeking a partner to jointly develop a cancer drug in the U.S. and Europe as it aims to replicate the success of a$2.9 billion dealwith AbbVie Inc., Bloomberg Newsreportedin June.</p>\n<p>Shares in I-Mab have almost doubled in the past year, giving the drug developer a market value of about $4.7 billion. The stock wasn’t spared in therecent routin U.S.-listed Chinese companies as investors shunned the assets amid a broad-based crackdown by regulators in Beijing. It has dropped about 22% in the last four trading days.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Drug Developer I-Mab Proceeds With Shanghai Dual Listing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Drug Developer I-Mab Proceeds With Shanghai Dual Listing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-28 13:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-07-28/chinese-drug-developer-i-mab-proceeds-with-shanghai-dual-listing><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I-Mab is progressing with its dual listing plans on Shanghai’s Nasdaq-style exchange as the drug developer seeks to expand its investor base.\nThe Chinese company’s board approved the proposed STAR ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-07-28/chinese-drug-developer-i-mab-proceeds-with-shanghai-dual-listing\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.bloomberg.com/news/articles/2021-07-28/chinese-drug-developer-i-mab-proceeds-with-shanghai-dual-listing","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107532514","content_text":"I-Mab is progressing with its dual listing plans on Shanghai’s Nasdaq-style exchange as the drug developer seeks to expand its investor base.\nThe Chinese company’s board approved the proposed STAR board listing and has hiredChina International Capital Corp.to work on its initial public offering tutorial, according to astatementTuesday. The company, which is traded in New York, aims to complete the Shanghai offering next year. It didn’t specify a fundraising target.\n”We are making concrete progress in our plan to pursue further equity listings on Greater China stock exchanges, including Shanghai Stock Exchange and Hong Kong Stock Exchange,” Jielun Zhu, chief financial officer of I-Mab, said in the statement. “The potential dual listing on the STAR board in China will enable us to tap into a complementary shareholder base in the onshore market.”\nBased in Shanghai, I-Mab focuses on treatments in the therapeutic areas of immuno-oncology and autoimmune diseases. It has a pipeline of more than 10 clinical and pre-clinical stage drug candidates, with offices in Beijing, Shanghai, Hangzhou, Hong Kong and the U.S.\nI-Mab raised about $114 million in a U.S. IPO in January 2020, followed by an additional share sale of $204 million earlier this year. The company is seeking a partner to jointly develop a cancer drug in the U.S. and Europe as it aims to replicate the success of a$2.9 billion dealwith AbbVie Inc., Bloomberg Newsreportedin June.\nShares in I-Mab have almost doubled in the past year, giving the drug developer a market value of about $4.7 billion. The stock wasn’t spared in therecent routin U.S.-listed Chinese companies as investors shunned the assets amid a broad-based crackdown by regulators in Beijing. It has dropped about 22% in the last four trading days.","news_type":1,"symbols_score_info":{"IMAB":0.9}},"isVote":1,"tweetType":1,"viewCount":379,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":5,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/803555528"}